Addressing the Ancestry Gap in Multiple Sclerosis Genetic Risk Prediction
Multiple sclerosis (MS) is a complex immune-mediated disease of the central nervous system, where the interplay between environmental factors and genetic predisposition plays a critical role. Modern genomic research has identified that MS risk is significantly influenced by polygenic inheritance, involving numerous small-effect genetic variants spread across the genome. To quantify this risk, researchers utilize Polygenic Risk Scores (PRS), which aggregate these variants into a single metric to identify high-risk individuals and stratify populations for clinical research. However, a significant limitation persists: most underlying genome-wide association studies (GWAS) have historically focused on populations of European ancestry, leading to concerns regarding the clinical utility of these scores in more diverse global populations.
Evaluating the All of Us Research Program Data
A recent cross-sectional study conducted by researchers at the Yale School of Medicine aimed to address this disparity by evaluating whether a standardized PRS for MS can effectively stratify individuals from non-European backgrounds. Utilizing the expansive "All of Us" Research Program database, the study analyzed prospectively collected data from 2018 to 2023. The cohort included participants who possessed both whole-genome sequencing data and comprehensive electronic health records (EHR), allowing for a robust comparison between genetic markers and clinical outcomes. This methodology provided a unique opportunity to test the performance of a 282-variant PRS in a real-world, diverse clinical setting.
Assessing Risk Stratification in European Populations
The study first established a baseline by examining individuals of European ancestry, where the PRS was expected to perform optimally. In this group, MS cases comprised approximately 1.0% of the population. The results confirmed a strong correlation: after adjusting for age, sex, and genetic principal components, individuals in the highest PRS quintile faced a 141% increase in the risk of MS compared to those in the lowest quintile. With an odds ratio (OR) of 2.41 and a highly significant p-value (p< 0.001), the PRS demonstrated a clear and reliable ability to partition European-ancestry individuals into distinct risk categories.
Performance in Latino and Admixed American Populations
One of the more encouraging findings of the research was the performance of the PRS in the Latino/admixed American population. Although the prevalence of MS in this group was lower, at roughly 0.46%, the genetic scoring system remained remarkably effective. The PRS successfully partitioned these individuals into increasing MS risk groups, showing an odds ratio of 2.56 for the highest risk quintile. This finding suggests that the genetic variants captured by European-centric GWAS may share enough commonality with Latino/admixed populations to maintain significant predictive power, facilitating better clinical stratification for these communities.
The Challenge of Genetic Diversity in African Ancestry
In stark contrast, the PRS failed to provide significant risk stratification for participants of African ancestry. While MS cases accounted for 0.56% of this population, the score did not effectively separate individuals into distinct risk categories, yielding an odds ratio of only 1.45 with a non-significant p-value (p=0.10). This lack of predictive accuracy highlights the profound impact of genetic diversity and the limitations of applying "one-size-fits-all" genetic tools across different ancestral backgrounds. The unique genetic architecture of African populations appears to require more tailored markers that are not currently captured by standard European-derived scores.
Implications for Precision Medicine and Clinical Trials
The inability of current PRS models to accurately predict MS risk in individuals of African ancestry has serious implications for equity in precision medicine. If genetic tools are used to screen for clinical trials or to guide early intervention, populations that are not well-represented in the data risk being excluded or misdiagnosed. The study authors emphasize that while PRS is a powerful tool for some, its current version cannot be universally applied without reinforcing existing health disparities. Ensuring that the benefits of genomic medicine reach all patients requires a fundamental shift in how we collect and analyze genetic data.
Moving Toward Ancestry-Specific Genetic Research
The conclusions of this study serve as a call to action for the scientific community to prioritize inclusivity in MS genetic research. The researchers highlight an urgent need for the development of ancestry-specific Polygenic Risk Scores to ensure accurate risk prediction across all diverse populations. By intentionally including non-European groups in future genome-wide association studies, scientists can uncover the specific genetic drivers of MS unique to those populations. Only through such representative research can we develop truly universal genetic tools that improve health outcomes for every individual, regardless of their ancestral background.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Rivier, C. A., Payabvash, S., Zhao, H., Hafler, D. A., Falcone, G. J., & Longbrake, E. E. (2024). Differential Results of Polygenic Risk Scoring for Multiple Sclerosis in European and African American Populations. medRxiv, 2024-06.
